DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

Monoclonal Antibody Therapy Authorized for COVID-19
August 5, 2021

Important Updates Regarding the Revised Emergency Use Authorization, Direct Order, and Reporting Process for REGEN-COV Monoclonal Antibody Therapy Continue reading


Newly Licensed Florida Practitioners Search Tool
July 29, 2021

Click here to access data on recently licensed Health Care Practitioners and Facilities
  Continue reading




Supporting Documents

Medical Degree Verification
NICA FORM
Postgraduate Training Verification
License Verification

Supporting Documents - Visiting Physician

NICA FORM